Literature DB >> 2542796

A potential basis for the thrombotic risks associated with lipoprotein(a).

L A Miles1, G M Fless, E G Levin, A M Scanu, E F Plow.   

Abstract

Lipoprotein(a) (Lp(a)) has been strongly linked with atherosclerosis and is an independent risk factor for myocardial infarction. Distinguishing Lp(a) from other low-density lipoprotein particles is its content of a unique apoprotein, apo(a). The recently described sequence of apo(a) indicates a remarkable homology with plasminogen, the zymogen of the primary thrombolytic enzyme, plasmin. Lp(a) may contain 37 or more disulphide-looped kringle structures, which are 75-85% identical to the fourth kringle of plasminogen. Plasminogen receptors are widely distributed on blood cells and are present at extremely high density on endothelial cells. These receptors promote thrombolysis by accelerating plasminogen activation and protecting plasmin from inhibition. If, by molecular mimicry, Lp(a) competes with plasminogen for receptors, then thrombolysis would be inhibited and thrombosis promoted. Here we provide support for such a mechanism being responsible for the thrombotic risks associated with elevated Lp(a) by demonstrating that Lp(a) inhibits plasminogen binding to cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2542796     DOI: 10.1038/339301a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  57 in total

Review 1.  Lipoprotein(a): its inheritance and molecular basis of its atherothrombotic role.

Authors:  A M Scanu
Journal:  Mol Cell Biochem       Date:  1992-08-18       Impact factor: 3.396

2.  Increased incidence of coronary disease in people with impaired glucose tolerance: link with increased lipoprotein(a) concentrations?

Authors:  M Davies; G Rayman; J Day
Journal:  BMJ       Date:  1992-06-20

3.  Lipoprotein(a)

Authors:  J Scott
Journal:  BMJ       Date:  1991-09-21

4.  Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation.

Authors:  J M Edelberg; M Weissler; S V Pizzo
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

5.  Lipoprotein (a) levels do not influence the outcome of rt-PA therapy in acute myocardial infarction.

Authors:  B Tranchesi; R Santos Filho; C Vinagre; B Caramelli; V Barbosa; O Gebara; G Belloti; F Pileggi; R Maranhão
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

6.  Expressed hypervariable polymorphism of apolipoprotein (a).

Authors:  M I Kamboh; R E Ferrell; B A Kottke
Journal:  Am J Hum Genet       Date:  1991-11       Impact factor: 11.025

7.  Highly repeated sites in the apolipoprotein(a) gene recognized by methylated DNA-binding protein, a sequence-specific DNA-binding protein.

Authors:  K C Ehrlich; M Ehrlich
Journal:  Mol Cell Biol       Date:  1990-09       Impact factor: 4.272

Review 8.  Vessel wall-related risk factors in acute vascular events.

Authors:  L Badimon; J J Badimon; M Cohen; J H Chesebro; V Fuster
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 9.  The annexin A2 system and vascular homeostasis.

Authors:  Elle C Flood; Katherine A Hajjar
Journal:  Vascul Pharmacol       Date:  2011-03-29       Impact factor: 5.773

Review 10.  Lipoprotein (a). Heterogeneity and biological relevance.

Authors:  A M Scanu; G M Fless
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.